Ureteral stents are indispensable tools in urologic practice. The main complications associated with ureteral stents are dislocation, infection, pain and encrustation. Biodegradable ureteral stents are one of the most attractive designs with the potential to eliminate several complications associated with the stenting procedure. In these work we hypothesize the impregnation of Ketoprofen, by CO₂-impregnation in a patented biodegradable ureteral stent previous developed in our group and validated in a pig model. It was evaluated of the in vitro elution profile in artificial urine solution(AUS) during degradation of a biodegradable ureteral stent loaded with ketoprofen. The biodegradable ureteral stents were developed according Barros et al. The biodegradable ureteral stents with each formulation: alginate-based, gellan gum-based (10 mg) were placed in high-pressure vessel with 10mg ketoprofen. The impregnation conditions used were 100bar, 2h and different temperatures were studied (35ºC, 40ºC and 50ºC). The impregnation was confirmed by FTIR and DSC. The in vitro release studied revealed an influence of the temperature in the impregnation, with 50ºC operating condition to obtain higher yield. Higher yield are obtained for gellan gum-based comparing the polymers used. According to the kinetics results (released exponent (n) was between 0.45<n<0.89) these systems are very promising for release ketoprofen in the first 72h in AUS. The non-cytotoxicity characteristic of the developed ketoprofen-eluting biodegradable ureteral stents was evaluated in L929 cell-line by MTS assay and demonstrated the feasibility of this product as a medical device. This study demonstrated   the possibility of combined eluting-drugs with a biodegradable ureteral stents for different urological targets (eg. Anticancer drugs).